Step Therapy Approval Criteria

Size: px
Start display at page:

Download "Step Therapy Approval Criteria"

Transcription

1 Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta (duloxetine) 5. Differin (adapalene) 6. Enbrel (etanercept) 7. Fenofibrate 8. Humira (adalimumab) 9. Imitrex Injection vial and STATdose (sumatriptan succinate) 10. Intuniv (guanfacine extended-release) 11. Lidoderm (lidocaine extended-release patch) 12. Nexium (esomeprazole) 13. Relpax (eletriptan)

2 14. Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) 15. Tivicay (dolutegravir) 16. Xifaxan (rifaximin)

3 Ambien CR (zolpidem ER) zolpidem extended-release Ambien CR Nonbarbiturate hypnotic Insomnia Previous failure of zolpidem (immediate-release tablet) in the past 180 days Quantity limit (QL) of 30 tablets per 30 days Initial: 10/01/2013 Revision:

4 Chantix Continuing Month (varenicline) varenicline Chantix Continuing Month Smoking cessation agent Smoking cessation assistance Previous claim for Chantix Starting Month in the past 90 days Quantity limit of 2 months total Initial: 12/10/2013 Revision:

5 Chantix Starting Month (varenicline) varenicline Chantix Starting Month Smoking cessation agent Smoking cessation assistance Previous failure of bupropion or nicotine replacement therapy (gum, lozenge or patch) in the past 365 days Quantity limit of 1 month total Initial: 12/10/2013 Revision: 04/01/2015

6 Cymbalta (duloxetine) duloxetine Cymbalta Serotonin-Norepinephrine reuptake inhibitor Chronic musculoskeletal pain Diabetic peripheral neuropathic pain Fibromyalgia Generalized anxiety disorder Major depressive disorder Previous failure of one of the following in the past 365 days: o Gabapentin o Venlafaxine ER o Formulary NSAID Step 2: Previous failure of one of the following in the past 365 days: o Formulary SSRI o Formulary TCA o Formulary muscle relaxant Quantity Limit (QL) of 60 capsules per 30 days Initial: 01/01/2015 Revision: 04/01/2015

7 Differin (adapalene) adapalene Differin Retinoid; antiacne Acne vulgaris Previous failure of a formulary topical acne medication (benzoyl peroxide, clindamycin, erythromycin or tretinoin) in the past 365 days Initial: 10/01/2013 Revision:

8 Enbrel (etanercept) etanercept Enbrel TNF inhibitor; immune suppressant Ankylosing spondylitis Juvenile idiopathic arthritis Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Previous failure of one of the following in the past 365 days: o Asacol o Balsalazide o Dipentum o Methotrexate o Rowasa Step 2: Previous failure of one of the following in the past 365 days: o Azathioprine o Cyclosporine o Hydroxychloroquine o Hydroxyurea o Leflunomide o Mercaptopurine o Soriatane o Sulfasalazine Quantity limit (QL) of 4 injections per 28 days Page 1 of 2

9 References: Beukelman T, Patkar NM, Saag KG, et al Amercian College of Rheumatology recommendation for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research 2011;63(4): Braun J, van den Berg R, Baraliakos X, et al update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70: Enbrel Prescribing Information. Immunex Corp, Thousand Oaks, CA: Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis in adults. American Journal of Gastroenterology 2010; available online at Accessed August 27, Lichtenstein GR, Hanauer SB, Sandborn WJ and The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn s disease in adults. American Journal of Gastroenterology 2009; available online at Accessed August 27, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Journal of the American Academy of Dermatology 2009;61: Singh JA, Furst DE, Bharat A, et al update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research 2012;64(5): Initial: 10/01/2013 Revision: 04/01/2015 Page 2 of 2

10 Fenofibrate Brand names: fenofibrate 54 mg, 134 mg and 160 mg Lofibra Fibric acid; antihyperlipidemic Hypercholesterolemia Previous failure of gemfibrozil in the past 180 days Quantity limit of 30 pills per month Initial: 04/01/2014 Revision:

11 Humira (adalimumab) adalimumab Humira TNF inhibitor; monoclonal antibody; antirheumatic Ankylosing spondylitis Crohn s disease Juvenile idiopathic arthritis Plaque psoriasis Psoriatic arthritis Rheumatoid arthritis Ulcerative colitis Previous failure of one of the following in the past 365 days: o Asacol o Balsalazide o Dipentum o Methotrexate o Rowasa Step 2: Previous failure of one of the following in the past 365 days: o Azathioprine o Cyclosporine o Hydroxychloroquine o Hydroxyurea o Leflunomide o Mercaptopurine o Soriatane o Sulfasalazine Quantity limit (QL) of 2 injections per 28 days Page 1 of 2

12 References: Beukelman T, Patkar NM, Saag KG, et al Amercian College of Rheumatology recommendation for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care and Research 2011;63(4): Braun J, van den Berg R, Baraliakos X, et al update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 2011;70: Humira Prescribing Information. AbbVie Inc, North Chicago, IL: Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis in adults. American Journal of Gastroenterology 2010; available online at Accessed August 27, Lichtenstein GR, Hanauer SB, Sandborn WJ and The Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn s disease in adults. American Journal of Gastroenterology 2009; available online at Accessed August 27, Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Journal of the American Academy of Dermatology 2009;61: Singh JA, Furst DE, Bharat A, et al update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research 2012;64(5): Initial: 10/01/2013 Revision: 04/01/2015 Page 2 of 2

13 Imitrex Injection vial and STATdose (sumatriptan succinate) sumatriptan Imitrex Injection vial and Imitrex STATdose 5HT-1 serotonin receptor agonist; antimigraine Acute migraine Cluster headache Previous failure of sumatriptan oral tablets or sumatriptan nasal spray in the past 365 days Quantity limit (QL) of 6 doses (3 ml) per 30 days Initial: 10/01/2013 Revision:

14 Intuniv (guanfacine extended-release) guanfacine extended-release Intuniv Alpha-2 adrenergic agonist Attention deficit hyperactivity disorder Previous failure of a formulary stimulant (amphetamine-containing product or methylphenidate-containing product) in the past 365 days Quantity limit (QL) of 30 tablets per 30 days Initial: 07/01/2015 Revision:

15 Lidoderm (lidocaine extended-release patch) lidocaine extended-release patch Lidoderm Local anesthetic Postherpetic neuralgia Previous failure of Voltaren Gel in the past 180 days Quantity limit (QL) of 30 patches per 30 days Initial: 07/01/2014 Revision:

16 Nexium (esomeprazole) esomeprazole Nexium Proton pump inhibitor H. pylori duodenal ulcer disease Erosive esophagitis Gastroesophageal reflux disease NSAID-associated gastric ulcer prophylaxis Zollinger-Ellison syndrome Previous failure of omeprazole in the past 365 days Step 2: Previous failure of pantoprazole in the past 365 days Quantity Limit (QL) of 30 capsules per 30 days Initial: 01/01/2015 Revision: 04/01/2015

17 Relpax (eletriptan) eletriptan Relpax 5-HT1 serotonin receptor agonist; antimigraine Acute migraine Previous failure of a formulary triptan medication (sumatriptan tablet, sumatriptan nasal spray, sumatriptan injection, zolmitriptan tablet or zolmitriptan oral-disintegrating tablet) in the past 180 days Quantity limit (QL) of 6 tablets per 30 days Initial: 10/01/2013 Revision:

18 Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir) elvitegravir/cobicistat/emtricitabine/tenofovir Stribild Antiretroviral HIV infection Previous failure of a regimen containing Reyataz, Prezista or Atripla in the past 365 days Initial: 10/01/2014 Revision: 04/01/2015

19 Tivicay (dolutegravir) dolutegravir Tivicay Antiretroviral HIV infection Previous failure of a regimen containing Reyataz, Prezista or Atripla in the past 365 days Quantity limit (QL) of 30 tablets per 30 days Initial: 10/01/2014 Revision: 04/01/2015

20 Xifaxan (rifaximin) rifaximin Xifaxan Rifamycin Hepatic encephalopathy, prophylaxis Traveler s diarrhea Previous failure of lactulose, ciprofloxacin or azithromycin in the past 180 days Quantity limit (QL) of 60 tablets per 30 days for the 550 mg tablets Quantity limit (QL) of 180 tablets per 30 days for the 200 mg tablets Initial: 07/01/2015 Revision:

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 01/01/2018 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab)

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: PA.CP.PHAR.247 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Cimzia ) is a tumor necrosis

More information

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form  Submit request via: Fax Prior Authorization Conditions for Approval of Humira (adalimumab) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Humira (adalimumab) require a prior

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If

More information

Amjevita (adalimumab-atto)

Amjevita (adalimumab-atto) *- Florida Healthy Kids Amjevita (adalimumab-atto) Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2 #* ^ prefilled

More information

C. Assess clinical response after the first three months of treatment.

C. Assess clinical response after the first three months of treatment. Government Health Plan (GHP) of Puerto Rico Authorization Criteria Tumor Necrosis Factor Alpha (TNFα) Adalimumab (Humira ) Managed by MCO Section I. Prior Authorization Criteria A. Physician must submit

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: PA.CP.PHAR.250 Effective Date: 01/18 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log Description (Enbrel ) is tumor necrosis

More information

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018

Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration. Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 Humira (adalimumab) Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 10/01/2015 Current Effective Date: 03/01/201811/01/2018 POLICY A. INDICATIONS The indications below including

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date: Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date:

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPA.167 Effective Date: Clinical Policy: (Cimzia) Reference Number: ERX.SPA.167 Effective Date: 1.1.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information.

More information

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form Submit request via: Fax

Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form   Submit request via: Fax Prior Authorization Conditions for Approval of Enbrel (etanercept) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Enbrel (etanercept) require a prior

More information

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ADALIMUMAB Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65

Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Market DC Amjevita (adalimumab-atto) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Amjevita 20 mg/0.4 ml prefilled syringe Amjevita (adalimumab-atto) 40 mg/0.8 ml 2

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Infliximab Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective

More information

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda)

Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) DRUG POLICY BENEFIT APPLICATION Remicade (infliximab) Inflectra (infliximab-dyyb) Renflexis (infliximab-abda) Benefit determinations are based on the applicable contract language in effect at the time

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade), Infliximab-dyyb (Inflectra), and Infliximab-abda (Renflexis) Reference Number: ERX.SPA.160 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other CERTOLIZUMAB PEGOL CIMZIA 35554 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a patient with a diagnosis of moderate

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Cimzia (Certolizumab pegol) - for Ankylosing Spondylitis, Crohn s Disease, Psoriatic Arthritis and Rheumatoid Arthritis POLICY NUMBER: PHARMACY-07 EFFECTIVE DATE: 5/2009 LAST REVIEW DATE: 6/13/2018

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda) Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease

More information

CLINICAL MEDICAL POLICY

CLINICAL MEDICAL POLICY Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Remicade (Infliximab) MP-026-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date: 9/17/2017 Revision

More information

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review

More information

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL 18830 GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Does the patient have a diagnosis of moderate to severe rheumatoid

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPMN.24

Clinical Policy: Certolizumab (Cimzia) Reference Number: ERX.SPMN.24 Clinical Policy: (Cimzia) Reference Number: ERX.SPMN.24 Effective Date: 10/2016 Last Review Date: 12/2016 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid

Clinical Policy: Etanercept (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Clinical Policy: (Enbrel) Reference Number: CP.PHAR.250 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this

More information

Pharmacy Medical Necessity Guidelines:

Pharmacy Medical Necessity Guidelines: Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date:

Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: Clinical Policy: Etanercept (Enbrel), Etanercept-szzs (Erelzi) Reference Number: ERX.SPA.07 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy

More information

Orencia (abatacept) DRUG.00040

Orencia (abatacept) DRUG.00040 Market DC Orencia (abatacept) DRUG.00040 Override(s) Prior Authorization Quantity Limit Approval Duration 1 year Medications Comments Quantity Limit Orencia (abatacept) - AGP, VA MCD only 4 vials per 28

More information

Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol)

Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Pharmacy Medical Necessity Guidelines: Cimzia (certolizumab pegol) Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 05.18 Line of Business: Medicaid Coding Implications Revision Log See

More information

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N 12/21/2016 Prior Authorization Aetna Better Health of West Virginia Humira (WV88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and

More information

PHARMACY POLICY STATEMENT Ohio Medicaid

PHARMACY POLICY STATEMENT Ohio Medicaid DRUG NAME BILLING CODE BENEFIT TYPE SITE OF SERVICE ALLOWED COVERAGE REQUIREMENTS LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY PHARMACY POLICY STATEMENT Ohio Medicaid Enbrel (etanercept) Must use

More information

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4. 06/01/2016 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date:

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPA.01 Effective Date: Clinical Policy: (Stelara) Reference Number: ERX.SPA.01 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Cimzia (certolizumab pegol)

Cimzia (certolizumab pegol) DRUG POLICY BENEFIT APPLICATION Cimzia (certolizumab pegol) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda)

Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximababda) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subject: Infliximab Page: 1 of 13 Last Review Date: December 8, 2017 Infliximab Description Remicade

More information

Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254

Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end

More information

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda) RATIONALE FOR INCLUSION IN PA PROGRAM Background Remicade, Renflexis and Inflectra are tumor necrosis factor (TNFα) blockers. Tumor necrosis factor is an endogenous protein that regulates a number of physiologic

More information

POLICY Document for REMICADE

POLICY Document for REMICADE POLICY Document for REMICADE The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific to use of preferred medication options, lower cost site

More information

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits.

1. Background: Infliximab is administered parenterally; therefore, it is not covered under retail pharmacy benefits. Subject: Infliximab (Remicade ) Original Original Committee Approval: October 13, 2006 Revised Last Committee Approval: December 3, 2008 Last Review: October 19, 2007 1. Background: Infliximab is a genetically

More information

Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin)

Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) 14 July 2015 Proposal relating to the funding of TNF inhibitors (Humira and Enbrel) and gabapentin (Neurontin) PHARMAC is seeking feedback on a proposal relating to the funding of the TNF-inhibitor medicines

More information

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab)

Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Pharmacy Medical Necessity Guidelines: Simponi and Simponi Aria (golimumab) Effective: November 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1041-8 Program Prior Authorization/Notification Medication Humira (adalimumab) P&T Approval Date 1/2007, 6/2008, 4/2009, 6/2009,

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and

More information

Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254

Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254 Clinical Policy: Infliximab (Remicade) and Infliximab-dyyb (Inflectra) Reference Number: CP.PHAR.254 Effective Date: 07/16 Last Review Date: 12/16 See Important Reminder at the end of this policy for important

More information

Inflectra Frequently Asked Questions

Inflectra Frequently Asked Questions Inflectra Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Earlier in 2016, Inflectra (infliximab) was added to the Ontario Drug Benefit (ODB) Formulary as a Limited

More information

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives

Rpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment

More information

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual

More information

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy? 09/23/2015 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Humira) Reference Number: CP.PHAR.242 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Adalimumab (Humira) Reference Number: CP.PHAR.242 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Humira) Reference Number: CP.PHAR.242 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date: Clinical Policy: (Orencia) Reference Number: ERX.SPA.123 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

NB Drug Plans Formulary Update

NB Drug Plans Formulary Update Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special

More information

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi

More information

2. Is the patient responding to Remicade therapy? Y N

2. Is the patient responding to Remicade therapy? Y N 09/29/2015 Prior Authorization AETA BETTER HEALTH OF MICHIGA (MEDICAID) Remicade (MI88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign

More information

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Certolizumab (Cimzia) Reference Number: CP.PHAR.247 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cimzia) Reference Number: CP.PHAR.247 Effective Date: 08.16 Last Review Date: 02.19 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Renflexis (infliximab-abda)

Renflexis (infliximab-abda) Renflexis (infliximab-abda) Last Review Date: 04/25/2017 Date of Origin: 04/25/2017 Dates Reviewed: 04/2017 Document Number: MODA-0300 I. Length of Authorization Coverage is provided for 6 months and may

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other GOLIMUMAB SIMPONI 22533, 22536, 34697, 35001 ROUTE = SUBCUTANE. GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the request for a

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log

More information

Drug Therapy Guidelines

Drug Therapy Guidelines Simponi, Simponi Aria Applicable Medical Benefit x Effective: 2/13/18 Pharmacy- Formulary 1 x Next Review: 12/18 Pharmacy- Formulary 2 x Date of Origin: 7/2010 Pharmacy- Formulary 3/Exclusive x Review

More information

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release)

Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Market DC Xeljanz (tofacitinib), Xeljanz XR (tofacitinib extended-release) Override(s) Prior Authorization Quantity Limit Medications Xeljanz (tofacitinib) Approval Duration 1 year Quantity Limit May be

More information

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

Remicade (infliximab)

Remicade (infliximab) Remicade (infliximab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 11/18/2003 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Carefirst.+.V Family of health care plans

Carefirst.+.V Family of health care plans Carefirst.+.V Family of health care plans CVS care mark POLICY Document for ENTYVIO The overall objective of this policy is to support the appropriate and cost effective use of the medication, specific

More information

First Name. Specialty: Fax. First Name DOB: Duration:

First Name. Specialty: Fax. First Name DOB: Duration: Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:

More information

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)? Humira (adalimumab) Medication Request Form (MRF) for Healthy Indiana Plan (HIP) and Hoosier Healthwise (HHW) FAX TO: (858) 790-7100 c/o MedImpact Healthcare Systems, Inc. Attn: Prior Authorization Department

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date:

Clinical Policy: Secukinumab (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: Clinical Policy: (Cosentyx) Reference Number: ERX.SPA.165 Effective Date: 10.01.16 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Subject: Remicade (Page 1 of 5)

Subject: Remicade (Page 1 of 5) Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Ustekinumab (Stelara) Reference Number: CP.PHAR.264 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Stelara) Reference Number: CP.PHAR.264 Effective Date: 08.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy

More information

Immune Modulating Drugs Prior Authorization Request Form

Immune Modulating Drugs Prior Authorization Request Form Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:

More information

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has

More information

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary Biologic Immunomodulators Prior Authorization with Quantity Limit (with a preferred option) OBJECTIVE The intent of the

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Infliximab (Remicade, Inflectra, Renflexis) Reference Number: CP.PHAR.254 Effective Date: 07.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log

More information

CIMZIA (certolizumab pegol)

CIMZIA (certolizumab pegol) Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance

More information

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167

Clinical Policy: Ustekinumab (Stelara) Reference Number: ERX.SPMN.167 Clinical Policy: (Stelara) Reference Number: ERX.SPMN.167 Effective Date: 10/16 Last Review Date: 12/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08.16 Last Review Date: 11.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144. MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,

More information

Pharmacy Prior Authorization

Pharmacy Prior Authorization Pharmacy Prior Authorization AETA BETTER HEALTH PESLVAIA & AETA BETTER HEALTH KIDS Humira (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date:

Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: Clinical Policy: Tofacitinib (Xeljanz, Xeljanz XR) Reference Number: ERX.SPA.110 Effective Date: 10.01.16 Last Review Date: 05.18 Revision Log See Important Reminder at the end of this policy for important

More information

Cosentyx. Cosentyx (secukinumab) Description

Cosentyx. Cosentyx (secukinumab) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx

More information

Erelzi (etanercept) Frequently Asked Questions

Erelzi (etanercept) Frequently Asked Questions Erelzi (etanercept) Frequently Asked Questions 1. What is the funding status of Erelzi (etanercept)? Effective December 21, 2017, Erelzi (etanercept) will be added to the Ontario Drug Benefit (ODB) Formulary

More information

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65

Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year

More information

Cimzia. Cimzia (certolizumab pegol) Description

Cimzia. Cimzia (certolizumab pegol) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review

More information

Appendix 1: Frequently Asked Questions

Appendix 1: Frequently Asked Questions Appendix 1: Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added to the Ontario Drug Benefit (ODB) Formulary

More information

Biologics for Autoimmune Diseases

Biologics for Autoimmune Diseases Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines

More information

HNMC. Interim Guidelines; Final Review and Approval by the P&T Committee Pending

HNMC. Interim Guidelines; Final Review and Approval by the P&T Committee Pending Coverage of drugs is first determined by the member`s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: AS CD UC NOMID pjia sjia

More information

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17

Clinical Policy: Secukinumab (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Clinical Policy: (Cosentyx) Reference Number: CP.PHAR.261 Effective Date: 08/16 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Pharmacy Medical Necessity Guidelines: Stelara (ustekinumab)

Pharmacy Medical Necessity Guidelines: Stelara (ustekinumab) Pharmacy Medical Necessity Guidelines: Effective: January 1, 2018 Type of Review Care Prior Authorization Required Management Not Covered Type of Review Clinical Review SQ: RX/ Pharmacy (RX) or Medical

More information

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions

Ontario Public Drug Programs. Inflectra (infliximab) Frequently Asked Questions Ontario Public Drug Programs Inflectra (infliximab) Frequently Asked Questions 1. What is the funding status of Inflectra (infliximab)? Effective February 25 2016, Inflectra (infliximab) will be added

More information

Proton Pump Inhibitors. Description

Proton Pump Inhibitors. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber

More information